瑞联新材(688550.SH)：2025年度净利润3.11亿元，同比增长23.48%

Core Viewpoint - 瑞联新材 (688550.SH) reported a strong performance for the fiscal year 2025, with significant growth in both revenue and net profit, driven by advancements in its pharmaceutical and electronic materials segments [1] Financial Performance - The company achieved an operating revenue of 1.677 billion yuan, representing a year-on-year increase of 14.95% [1] - The net profit attributable to shareholders reached 311 million yuan, marking a year-on-year growth of 23.48% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 306 million yuan, reflecting a year-on-year increase of 28.90% [1] Segment Performance - The revenue growth in 2025 was primarily driven by the pharmaceutical and electronic materials segments [1] - In the pharmaceutical segment, sales revenue increased due to clients adjusting inventory strategies and a further increase in core product sales [1] - The electronic materials segment saw growth as the company successfully advanced its semiconductor photoresist monomer material validation and introduced some packaging materials products [1] Operational Efficiency - The company focused on enhancing operational management efficiency and deepening cost reduction and efficiency improvement measures [1] - Efforts included cost savings, process optimization, and strengthening the coordination of research, production, supply, and sales to lower production costs and enhance profitability [1]